$CYTO “Ultimate Stock Alerts” Promoter Rank: 22/22 Altamira Therapeutics Ltd. Newsletter 7:41:17 AM May 19, 2022

on May 19, 2022 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "Ultimate Stock Alerts"

The following three charts can be used by potential investors to gauge the performance of "Ultimate Stock Alerts":

28%

2 out of 7 campaigns closed down on first day

28%

2 out of 7 campaigns closed up on first day

42%

3 out of 7 campaigns had no net effect

CYTO Promotional Newsletter

The following is a newsletter released by "Ultimate Stock Alerts" promoting Altamira Therapeutics Ltd.

Caution

The following newsletter has not been verified for accuracy or completeness.

UltimateStockAlerts

Don't Want Anymore Emails

Hello

New Alert Altamira Therapeutics Ltd. NASDAQ CYTO

CYTO is dedicated to developing therapeutics that address important unmet medical needs.

In 2021, CYTO laid the groundwork to transform the Company through its Trasir acquisition to enter RNA therapeutics -- which it believes to be one of the most exciting and dynamic fields in medicine.

As the company explains, Trasir is a pioneer in the development of nanoparticles for extrahepatic nucleic acid delivery, that is of RNA molecules to targets outside the liver.

In January, the company stated, The Company's U.S. subsidiary, Altamira Therapeutics Inc., was recently awarded a Small Business Technology Transfer STTR grant by the National Institutes of Health NIH to help address the lack of effective systemic delivery technologies for RNA structures that might target diseases occurring beyond the liver.

In addition, the company also continues to progress towards upcoming key catalysts with its non-RNA legacy programs.

The Company is currently active in three areas

the development of RNA therapeutics for extrahepatic therapeutic targets OligoPhore SemaPhore platforms preclinical

nasal sprays for protection against airborne viruses and allergens Bentrio commercial or the treatment of vertigo AM-125 Phase 2

the development of therapeutics for intratympanic treatment of tinnitus or hearing loss Keyzilen and Sonsuvi, Phase 3

The nasal mucosa is the bodys first line of defense against airborne viruses or allergens as it functions as a barrier and helps to clear such particles from the nose.

The companys drug-free nasal spray technology reinforces these mucosal defenses by forming a thin protective film on the mucosa, trapping particles and moisturizing the mucosa through physical effects, providing natural protection.

Bentrio AM-301 is a drug-free nasal spray intended for personal protection against airborne viruses and allergens.

As the company further explains

Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa.

Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms.

Importantly

In human nasal epithelium cells infected by SARS-CoV-2, Bentrio was shown to reduce the infectious viral load by more than 99% when used for prevention.

Further, Bentrio was effective in slowing the growth of the viral titer when treatment started only 24 or 30 hours after infection.

Plus, as the company recently mentioned, Bentrio offers an affordable, drug-free means of protection against airborne viruses and allergens.

Since the start of the year, the company announced multiple accomplishments

Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia

Here are the companys comments from this press release

We are very pleased with the swift go-to-market' progress in Malaysia and Singapore, commented Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. Together with our partner, Wellesta, we look forward to making Bentrio available to consumers in these dynamic countries for the protection against airborne allergens and viruses. As previously indicated, we expect Bentrio sales in Asian markets to significantly contribute to our 2022 revenues.

In February, the company entered into an agreement for the marketing and distribution of Bentrio the Agreement, its nasal spray for protection against airborne viruses and allergens, with Avernus Pharma Ltd., Dubai Avernus in the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Oman and Bahrain the Territories.

In addition, in February, the company also announced that the geographic scope of its existing marketing and distribution agreement the Agreement for Bentrio with Wellesta Holding Pte Ltd Wellesta has been expanded. In addition to India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam, Wellesta will now also promote and sell Bentrio in the Philippines and Morocco upon registration of the product with the regulatory agencies in those two countries.

Furthermore, just in the past few months, CYTO has announced multiple developments.

In March, the company announced

Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets

Here are the highlights from this press release

Nuance Pharma to develop and commercialize Bentrio nasal spray in Chinese Mainland, Hong Kong, Macau and South Korea

Altamira to receive up to $23.5 million in upfront and milestone payments during initial phase of supply Bentrio to Nuance

Altamira to receive royalties on sales following start of local production of Bentrio by Nuance

In addition, the company also announced

Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19

Here are the companys comments from this press release

After demonstrating Bentrio's safety and efficacy in helping to protect patients against airborne allergens, we are excited to start the clinical assessment of our innovative nasal spray also in airborne viral infections, commented Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. Multiple in vitro studies of Bentrio using human nasal epithelia cells infected with the SARS-CoV-2 virus or the H1N1 virus have demonstrated a significant reduction of the viral titer with either prophylactic or therapeutic application. We now look forward to testing Bentrio in the treatment of COVID-19 under clinical conditions to evaluate and confirm the effectiveness of its triple mode of action, which comprises the formation of a protective film on the nasal mucosa, the trapping of virus particles and the humidification of the mucosa.

In April alone, the company announced multiple accomplishments

Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its BentrioTM Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant

Here are the highlights from this press release

Study Confirms in vitro Efficacy Safety of BentrioTM for Delta Variant

Prophylactic treatment of human nasal mucosa with Bentrio was reported to significantly reduce the viral titer vs. controls over 4 days, reaching a maximum reduction of 99% with the wild-type SARS-CoV-2 variant and more than 83% with the Delta variant

Bentrio administered 24 hours after infection saw the viral titer decrease by approximately 12-folds, and 3-folds on Day 4

Bentrio recently showed positive in vitro test results also against the Omicron variant in separate study

In addition, the company also announced

Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results

Here are the companys highlights from this press release

Company pivots towards RNA therapeutics and its OligoPhore SemaPhore platform for extrahepatic RNA deliver

Established new business unit, OTC Consumer Health, to support global commercialization of Bentrio nasal spray and successfully established distribution partners covering more than 20 countries so far.

Reported completion of enrollment into Bentrio house dust mite clinical trial with expected top-line results planned for 2Q-22, and initiation of COVAMID clinical trial in acute COVID-19.

Completed patient enrollment in Part B of Phase 2 TRAVERS' clinical trial evaluating AM-125 in acute vertigo expects to release top-line results in 2Q-22.

As the company explained in this announcement

As we are moving towards important clinical and regulatory milestones with our legacy programs, we have been preparing for the second step of our transformation, the planned divestiture or spin-off of our legacy business targeted for the second half of 2022, Mr. Meyer added. With that step, Altamira shall become an RNA therapeutics focused company with disruptive prospects, while unlocking the intrinsic value of our legacy business.

In addition, the company also recently announced

Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19

As the company further explained

COVAMID is a randomized, placebo controlled clinical trial to evaluate the ability of Bentrio nasal spray to reduce the SARS-CoV-2 viral load in the nose, alleviate COVID-19 signs and symptoms, and decrease the frequency of COVID-19 related hospital admissions. In the COVAMID trial, 136 confirmed via a positive PCR test COVID-19 patients will be randomized at a 211 ratio to receive for 10 days either Bentrio, a placebo Bentrio minus its key mineral component, or no treatment, followed by a 10-day observation phase. Depending on the outcomes from a pre-specified blinded interim analysis, the number of participants may be increased to a maximum of 180 COVID-19 patients. The COVAMID study began in Bulgaria in early March 2022.

Here are the companys comments from this press release

We are pleased to have reached this important interim milestone in the COVAMID trial, commented Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. Clinically, we have already demonstrated the protective effects of Bentrio against airborne allergens. With COVAMID, we expect similar results for airborne viruses, which will be essential for the broader marketing of Bentrio as a viral infection therapeutic. So far, multiple in vitro studies with Bentrio on human nasal epithelia cells have demonstrated a significant reduction of the viral titer with either prophylactic or therapeutic applications.

Most recently, the company announced

Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia

Here are the companys comments from this press release

Extending our study into North Macedonia strengthens our ability to meet our recruitment objectives for the COVAMID trial, commented Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. We are pleased to further expand the number of study sites in accordance with our initial plans and to increase the overall recruitment potential. Subject to sufficient COVID-19 cases, we continue to expect completion of the COVAMID trial in 3Q 2022.

In addition, yesterday, the company announced

Altamira Therapeutics Issues Shareholder Letter

Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM

CYTO could be in a position to experience increased growth.

Make sure to do your own due diligence.

Sources , , , , , , , , , , , , , , , ,

Happy Trading

UltimateStockAlerts

Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.

-------

DISCLAIMER

You should read and understand this disclaimer in its entirety before joining the website or emailblog list of UltimateStockAlerts.com the Publisher. The information collectively the Advertisement disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, andor losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission the SEC at www.sec.gov the Financial Industry Regulatory Authority the FINRA at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.govconsumercyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial andor legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

Owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 51622 for the distribution of this advertisement about CYTO dated 51922. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.

You are receiving this reportrelease because you subscribed to receive it at our website or through a third-party site. All our newsletters include an unsubscribe link, and you can remove yourself at any time from our newsletters by clicking on that unsubscribe link. You can also contact us at infoUltimateStockAlerts.com to change your information at any time. By your subscription to our profiles, the viewing of this profile andor use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link

www.UltimateStockAlerts.comDisclaimer and www.UltimateStockAlerts.comPrivacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of 1 a client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.

Our records indicate that . requested and confirmed to be added to UltimateStockAlerts.com on January 26, 2015.

6020 Bent Pine Dr, Orlando, FL 32822, USA